Abstract
Liechty and Bangsberg made the case that the enthusiasm for HIV directly observed treatment (DOT) programmes is premature and they show that there is little evidence as yet that DOT for antiretroviral drugs improves virological immunological or clinical outcomes. The enthusiasm for HIV DOT stems from the experience of tuberculosis control programmes in which the direct observation of treatment is promoted as one part of an overall strategy for tuberculosis control. Criticism of HIV DOT may be valid but it misses the point and detracts from the overall message that the strategy for tuberculosis control might be a useful model on which to base a strategy for delivering antiretroviral therapy. (excerpt)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
